Limited efficacy of current therapeutic approaches for neurodegenerative disease has led to increased interest in alternative therapies. Cord blood plasma (CBP) derived from human umbilical cord blood (hUCB) may be a potential therapeutic. A recent study 7 showed beneficial functional improvement in an --
Alzheimer's disease (AD) mouse model by injection of a specific fraction from cord blood serum compared to adult blood serum. Additionally, umbilical cord serum has being effectively employed for the treatment of corneal defects 8, 9 and neurotrophic keratitis 10 in humans.
In a relatively recent study, 11 we showed the ability of CBP to modulate mitogen-induced in vitro proliferation of mononuclear cells (MNC) isolated from the peripheral blood of amyotrophic lateral sclerosis (ALS) patients. Interestingly, three distinct cell responses to the mitogenic factor phytohemmagglutinin were noted, suggesting altered lymphocyte functionality in ALS patients. MNC responses were shown to be regulated by CBP treatment in vitro. Additionally, the apoptotic activity of MNCs isolated from ALS patients was significantly reduced by supplementing media with CBP. Thus, these study results have not only broadened the therapeutic application of CBP for ALS, but also further expanded its potential for treatment of other neurodegenerative disorders with immunological aspects.
It has been shown that CBP contains high amounts of various growth factors, such as vascular endothelial growth factor (VEGF),
insulin-like growth factor-1 and transforming growth factor (TGF)-β, that are required for cell maintenance during hematopoiesis. 3, 12 Although CBP can exert a favourable effect on hematopoietic stem cells, whether CBP elicits therapeutic benefit as an additive to, or substitute for, cells must be determined before developing clinically relevant CBP-based therapies for various neurodegenerative diseases.
The aim of this study was to characterize the composition of factors in CBP derived from hUCB, which might mediate therapeutic benefit. First, cytokine and growth factor profiles were analyzed in the same CBP samples. Second, the efficacy of autologous CBP on MNC hUCB viability in vitro was investigated. Finally, the effect of autologous CBP upon the apoptotic MNC hUCB response in vitro was examined. These study results provide a basis for further establishment of CBP as a potential self-contained therapeutic or as a supportive diluent for MNC hUCB infusion in treatment of neurodegenerative diseases.
| MATERIALS AND METHODS

| Ethics statement
The human umbilical cord blood (hUCB) units were collected by
Texas Cord Blood Bank (TCBB, GenCure, West San Antonio, TX, USA) and provided to Saneron CCEL Therapeutics, Inc. for research purposes. The cord blood units were obtained from full-term pregnancies by vaginal delivery. The umbilical cord blood units were received within 48 hours of collection. Maternal blood samples, collected as the same time as the cord blood, were tested by TCBB for infectious disease markers of HIV, hepatitis B and C, syphilis, CMV and HTLV I&II, and test results were provided for validation of the cord blood units. Each cord blood unit in the study was negative for all infectious disease markers as determined in maternal blood.
Human adult blood plasma or sera (ABP/S) was obtained from a commercially available source (Sigma-Aldrich, St. Louis, MO, USA).
Upon receipt of ABP/S, samples were aliquoted and stored at −20°C.
| Human umbilical cord blood processing and plasma isolation
Human umbilical cord blood (hUCB) units (n = 20), with maternal
blood samples negative for all tested infectious markers, were processed to obtain an autologous CBP fraction and mononuclear cell population (MNC hUCB, U-CORD-CELL 
| Viability of MNC hUCB cultured with autologous CBP
Cryopreserved MNC hUCB cells (n = 4 units) were quickly thawed at 37°C, washed with PBS, and centrifuged at 400 g for 5 minutes.
Cell quantity and viability were determined using a haemocytometer. 
| Apoptotic activity of MNC hUCB cultured with autologous CBP
Cryopreserved MNC hUCB cells (n = 6 units) were quickly thawed at 37°C, washed with PBS, and centrifuged at 400 g for 5 minutes.
Cell quantity and viability were determined using a haemocytometer.
Cells were then re-suspended with phenol-free RPMI-1640 media and plated in a 96-well culture plate at a density of 2 × 10 4 cells/ well. Pre-designated wells were supplemented with 10% of either autologous CBP, ABP/S, or FBS upon initial plating in duplicate. Cells were incubated at 37°C with 5% CO 2 for 5 days. Media was changed at 24 hours and 3 days after cell plating. On day 5, the apoptotic activity of the cells was determined using the HT TiterTACS 
| Statistical analysis
Data was presented as mean ± SEM Statistical analysis was performed using GraphPad Prism Software version 5 (GraphPad Software, Inc.). The results for MNC hUCB viability and apoptotic activity were evaluated using a one-way ANOVA with Tukey's Multiple Comparison post-hoc test. The results for cytokine and growth factors in CBP were analyzed with a two-tailed t test using same software. A value of P < 0.05 was considered significant.
| RESULTS
| Cord blood plasma cytokine profile
Samples of CBP and ABP/S were assayed to determine cytokine profiles using an ultrasensitive human cytokine 10-plex panel. Results Table 1A .
| Cord blood plasma growth factor profile
The levels of several common growth factors were measured in CBP and ABP/S using a human growth factor four-plex assay. The concentrations of VEGF were significantly (P < 0.01) higher in CBP, more than two-fold, vs. ABP/S (Figure 2A) . The concentrations of G-CSF, a bone marrow stem cell stimulating growth factor, were also significantly (P < 0.05) higher in CBP compared to ABP/S ( Figure 2B) . T A B L E 1 Cytokine and growth factor profiles in cord blood plasma and adult blood plasma/serum Significance of CBP vs. ABP/S denoted by: *P < 0.05; **P < 0.01.
F I G U R E 2
Cord blood plasma growth factor profile. The levels of the growth factors were analyzed in CBP (n = 20) and ABP/S (n = 6) using a human growth factor multiplex assay in triplicate. Significantly higher concentrations of (A) VEGF, (B) G-CSF, (C) EGF and (D) FGF basic growth factors were detected in CBP vs. ABP/S. *P < 0.05, **P < 0.01 function in both aged wild-type mice 14 and a mouse model of Alzheimer's disease (AD). 15 Middeldorp et al 15 demonstrated that parabiosis of young wild-type mice with AD mice for 5 weeks effectively improved learning and memory while also reducing inflammation in AD mice. Additionally, the authors noted increased synaptic activity in the hippocampus of AD mice. Based on these study results, clinical trial (NCT02256306) investigated the safety of 4-weekly infusions of young blood plasma from donors aged between 18 and 30 years of age into patients with AD. Although no serious adverse reactions occurred, the study found no significant effect on patient cognition but did show significant improvements in daily living skills.
Although results of using young blood are promising, it is still unclear which constituents of "young" blood are providing beneficial effects.
Potentially, paracrine actions are involved in positive outcomes for treatment of an age-related disease such as AD. Also, hormonal status of donors should be investigated due to the wide age range (18-30 years) of donors. Alternatively, plasma derived from hUCB could be a more beneficial therapeutic due to its unique and uniform molecular composition.
It has been shown that in addition to a high concentration of growth factors (reviewed 16 ), human CBP also contains a great amount of soluble proliferative and immunomodulatory factors such as (TGF)-β, G-CSF, GM-CSF, monocyte chemoattractant protein (MCP)-1, IL-6, and IL-8. 17 Also, IL-16 cytokine, a modulator of T cell activation, has been detected in CBP 18 and potentially presents a physiological mechanism for foetal-maternal tolerance. Due to CBP's specific molecular composition, numerous studies [1] [2] [3] [4] showed beneficial effect of CBP in replacement of standard FBS for various cell expansions in vitro, which may be essential to achieve appropriate cell numbers for clinical use.
In our study, cytokine and growth factor levels were analyzed in the same CBP samples for a better understanding of CBP molecular composition prior to proposing CBP as a therapeutic agent. We ing that the delivery method impacts oxidative stress. 21 In our study, the low concentration of GM-CSF found in CBP together with the low concentrations of pro-inflammatory cytokines provide further evidence of anti-inflammatory hUCB content. Thus, low levels of pro-inflammatory and immunomodulatory cytokines in CBP provide a favourable microenvironment for cellular content in hUCB. It has been shown that transplantation of MNC derived from hUCB even from unrelated donors into patients with haematologic malignancies causes a low incidence of graft-versus-host disease compared to bone marrow or peripheral blood cell administration. 22, 23 Our study results also demonstrated similar amounts of antiinflammatory IL-4 and IL-10 cytokines in CBP and ABP/S, However, it is important to note that these anti-inflammatory cytokines were present at a greater concentration than the pro-inflammatory constituents of CBP, suggesting a favourable cytokine composition towards developing CBP as potential therapeutic agent. Since IL-10
is an important cytokine for downregulation of Th1 inflammatory cytokines and MHC class II antigens, a decrease of this cytokine is mainly associated with altered cell-mediated immunosuppression and induction of complications during pregnancy. 24 In contrast, increased cord blood IL-10 was determined in preterm infants compared to full-term newborns. 25, 26 In our study, hUCB units were used from healthy infants delivered naturally, so IL-10 levels determined in CBP Exclusively, VEGF has been studied for potential therapeutic efficacy in animal models of ALS 38, 39 and its use in clinical settings has been discussed (reviewed 40 ). Nevertheless, CBP containing high levels of 5 or into an animal model of ageing. 6 In these studies, multiple injections of CBP were performed and this therapeutic approach needs to be considered. In agreement with this approach, repeated deliveries of CBP could provide ongoing trophic support for damaged cells and/or tissues. Our study showed that CBP is a potential therapeutic due to its unique composition. We are planning in the near future to determine the effect of CBP alone and in combination with MNC hUCB for treatment of ALS using a symptomatic animal model of disease for a translational perspective.
In conclusion, our study results demonstrate uniquely protein 
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